Helix BioPharma Corp. Appoints New Independent Chair of the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Helix BioPharma Corp. Appoints New Independent Chair of the Board

AURORA, ONTARIO--(Marketwired - July 21, 2014) -  Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.

"I am very pleased Mr. Bastien has accepted the role of board Chair," said Mr. Verhagen. "As a result of his current service on Helix's Board we have already experienced firsthand his vast amount of knowledge from his involvement in the life science industry both in a leadership capacity and at the board level. I am confident that Helix can only be strengthened going forward with Mr. Bastien as Board Chair."

Following his appointment, Mr. Bastien said, "On behalf of the board, I would like to thank Mr. Verhagen for his service as interim Chair during the past seven months, and I thank the board of Helix for their confidence in me. I am excited to work closely with both management and all board members to optimize the development of Helix's oncology portfolio and to continue to work to create value for patients and all stakeholders."

Mr. Bastien has served in leadership roles within the life sciences industry for over 30 years, most recently as past President of Sanofi Canada and past President of Jouveniel. He has also served in executive roles at CIBA Geigy in Switzerland, Laboratoire Debat in Paris, IMS Canada in Montreal, and Eli Lilly in Montreal. He currently serves as chairman of the board for two health care companies and is a director of Bioniche Life Sciences. He previously served as chairman of the board for two other biotech companies.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Investor Relations: Helix BioPharma Corp. Tel: +1 (905) 841-2300 Email: ir@helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 165

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 58

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 153

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 148

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 247

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 89

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading

Top 5 Most Recently Viewed Articles

Verizon Secures $66 Million EIS Partnership with Coast Guard

Updated Category News Views 283

Verizon Awarded $66 Million Enterprise Infrastructure Solutions Contract In a significant development, Verizon Business has been awarded a substantial contract valued at up to $66 million by the U.S. Coast Guard. This eight-year Enterprise Infrastructure Solutions (EIS) task order represents a robust commitment to enhancing the Coast Guard's communication and operational...

Continue Reading
Icelandic Glacial Becomes Laver Cup 2025's Official Water

Updated Category News Views 168

Icelandic Glacial to Hydrate Laver Cup 2025 Attendees Icelandic Glacial™, recognized for its exceptional quality and purity, has been designated as the Official Water for the highly anticipated Laver Cup 2025. This prestigious tournament is scheduled to take place at the Chase Center, showcasing top-tier men's tennis. A Perfect Fit for a Grand Event Coming from the...

Continue Reading
Dick's Sporting Goods Shows Promise for Q3 Amid Market Trends

Updated Category News Views 196

Dick's Sporting Goods Anticipates Strong Q3 Results Dick's Sporting Goods Inc. (NYSE: DKS) is gearing up for its fiscal third-quarter earnings report, creating buzz among investors eager to understand how the retailer is managing consumer demand and its recent strategic moves. As the company prepares to disclose its earnings, the market remains cautiously optimistic,...

Continue Reading
HyOrc Corporation Charts New Path with Green Fuel Innovations

Updated Category News Views 165

HyOrc Corporation's Strategic Market Transformation HyOrc Corporation (OTCID: HYOR) is making significant strides in the clean energy sector with a recent change in its trading symbol on the OTC markets. This evolution reflects not only a fresh identity but also the dynamic advancements the company is achieving in green fuel technologies and hydrogen mobility....

Continue Reading
Exploring Nature Through Art: BlackBook's New Exhibition

Updated Category News Views 227

BlackBook Presents Unveils a Unique Art Exhibition BlackBook Presents is set to embark on an exciting journey with its upcoming art exhibition titled Mother Nature in the Bardo. This innovative presentation, in collaboration with UNESCO's GEM Report, aims to foster meaningful discussions about art, culture, and their profound connection to environmental issues. Through an...

Continue Reading